Prognostic value of pretreatment and recovery duration of cranial nerve palsy in nasopharyngeal carcinoma by Hao-Yuan Mo et al.
Mo et al. Radiation Oncology 2012, 7:149
http://www.ro-journal.com/content/7/1/149RESEARCH Open AccessPrognostic value of pretreatment and recovery
duration of cranial nerve palsy in nasopharyngeal
carcinoma
Hao-Yuan Mo1,2†, Rui Sun1,2†, Jian Sun1,3, Qing Zhang4, Wen-Jin Huang5, Yan-Xian Li1,2, Jing Yang1,2
and Hai-Qiang Mai1,2*Abstract
Background: The purpose of this study was to evaluate the prognostic value of cranial nerve (CN) palsy in
nasopharyngeal carcinoma (NPC) patients.
Methods: A retrospective analysis was performed on CN involvement using medical records of 178 consecutive
patients with histologically diagnosed, non-disseminated NPC.
Results: In 178 NPC patients with CN palsy, the 5-year survival rates were as follows: overall survival (OS), 61.0%;
disease-specific survival (DSS), 69.6%; local relapse-free survival (LRFS), 75.2%; distant metastasis-free survival (DMFS),
73.4%; and disease-free survival (DFS), 55.3%. Significant differences were observed in the 5-year OS rates between
patients with single and multiple CN palsy (69.8% vs. 54.3%; P = 0.033) and the OS rates between patients with
different pretreatment durations (68.7% vs. 43.3%, P = 0.007). However, no significant differences were observed in
OS, DSS, LRFS and DFS rates between patients with upper and lower CN palsy (P = 0.581, P = 0.792, P = 0.729 and
P= 0.212, respectively). The results showed that recovery duration was an independent prognostic factor for OS
(HR = 2.485; P < 0.001), DSS (HR = 2.065; P = 0.016), LRFS (HR = 3.051; P = 0.001) and DFS (HR = 2.440; P < 0.001).
Conclusions: Recovery duration is an independent prognostic factor for NPC patients with CN palsy and is related
to recurrence, which leads to poor survival. Recovery duration requires close surveillance and different treatment
regimens.
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PrognosisBackground
Cranial nerve (CN) palsy in nasopharyngeal carcinoma
(NPC) is the result of an adjacent extension of the pri-
mary tumor. CN palsy occurs in 8.0 to 12.4% of cases
[1]. Cranial nerve involvement is considered an un-
favourable prognostic factor for NPC patients, and those
with CN palsy have been classified as T4 according to* Correspondence: maihq@mail.sysu.edu.cn
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reproduction in any medium, provided the orthe staging system of NPC in the seventh edition of the
American Joint Committee on Cancer (AJCC) [2]. The
patients with extensive CN palsy had worse survival
rates than those with only upper CN or lower CN in-
volvement [3]. Moreover, the patients who recovered
from CN palsy had better survival rates than those who
did not. However, no recent research has indicated the
prognostic value of the pretreatment or recovery dura-
tions for NPC patients with CN palsy.
The diagnosis of CN palsy mostly depends on clinical
symptoms and a physical examination, and magnetic
resonance imaging (MRI) has proven to be an important
tool for defining CN involvement in NPC [4-6]. How-
ever, CN palsy frequently accompanies skull-base inva-
sion in upper CN palsy and carotid sheath erosion in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics (n = 178)
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basicranial to intracranial or orbital sites, and carotid
sheath erosion will extracranially involve lower CN
palsy. Previous studies have focussed only on survival
rates and imaging diagnoses in NPC patients with and
without CN palsy, and those studies did not indicate the
prognostic value of the pretreatment or recovery dura-
tions in NPC patients with CN palsy.
The National Comprehensive Cancer Network (NCCN)
has recommended concurrent chemoradiotherapy plus
adjuvant or induction chemotherapy as the standard treat-
ment for patients with CN palsy. However, it is important
to understand whether similar chemotherapy cycles and
radiotherapy doses benefit NPC patients with CN palsy
with different pretreatment and recovery durations.
Hence, research on the prognostic value of the pretreat-
ment and recovery durations of NPC patients with CN
palsy was performed with a large sample size. Because the
pretreatment program design is very important, in this
study, we aimed to grade the pretreatment and recovery
durations of NPC patients with CN palsy and to precisely
judge patient prognosis. The results of this study may help
to develop individualised treatment for NPC patients [7].
Methods
Patients
We reviewed the records of consecutive NPC patients
referred to our center between January 1, 2002, and
December 31, 2003. During the study period, there were
1,892 primary NPC patients who received radiation ther-
apy in our institution. Of these patients, we identified
178 NPC patients with CN palsy (9.4%; 178/1892) who
had completed radical treatment during the study
period. All clinical records were reviewed by the authors.
Of these patients, 145 patients were male, and 33 were
female (a male-to-female ratio of 4.4:1). The patients
had biopsy-proven NPC without distant metastases and
were treated radically with radiation. The median age of
the 145 male patients was 47.7 years (range, 18–
74 years), and the median age of the 33 female patients
was 45.3 years (range, 21–67 years).
The CN palsy diagnosis was mainly based on clinical
symptoms and a physical examination. At histologic
examination, 174 of the 178 patients (97.8%) were classi-
fied as having type II or III disease based on the World
Health Organization criteria. Three patients (1.7%) were
classified as having type I disease; the remaining patient
(0.5%) had an adenocarcinoma. All patients underwent a
pretreatment evaluation that included a complete patient
history, physical and neurologic examinations, haemato-
logical and biochemical profiles, MR imaging of the neck
and nasopharynx, chest radiography and abdominal
ultrasonography. Medical records were retrospectively
analysed, and all patients were staged according to thestaging system of the seventh edition of the American
Joint Committee on Cancer. The stage distribution for
the patients was as follows: 10.1% of patients (18/178)
belonged to clinical stage IVb with N3 classification;
other patients belonged to clinical stage IVa with T4
classification, including 16.3% of patients (29/178) classi-
fied as N0; 51.7% (92/178) as N1; and 21.9% (39/178) as
N2. Table 1 shows the characteristics of all patients.
Treatment
All patients were treated with radical radiotherapy. The
details of the radiation therapy techniques used at the
Cancer Center of Sun Yat-sen University have been
described previously [8-10]. In brief, most patients (146/
178; 82.0%) were treated with conventional techniques,
13.5% (24/178) received intensity-modulated radiation
therapy (IMRT) and 4.5% (8/178) were administered 3-
dimensional conformal radiation therapy (3D-CRT).
A total of 44 of 178 patients (24.7%) were treated with
radiotherapy only. A total of 134 of 178 patients (75.3%)
received chemotherapy, including various regimens of
concurrent chemotherapy combined with either induc-
tion chemotherapy or adjuvant chemotherapy in con-
junction with a platinum-based therapeutic clinical trial.
Deviations from the guidelines were due to advanced
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or hepatic function, which suggested intolerance to
chemotherapy. When possible, salvage treatments, such
as neck dissection and chemotherapy, were provided in
the event of documented relapse or persistent disease.
Follow-up and statistical analyses
The duration of patient follow-up was calculated from
the first day of treatment to either the day of death or
the day of the last examination. The patients were exam-
ined at least every 3 months during the first 2 years;
thereafter, a follow-up examination was performed every
6 months for up to 5 years or until death. The time of
last follow-up was March 2010, and the median follow-
up period was 61.4 months (range, 2.5–86.6 months).
All events were measured from the date of treatment
commencement. The following end points (time to the
first defining event) were assessed: overall survival (OS);
disease-specific survival (DSS); local relapse-free survival
(LRFS); distant metastasis-free survival (DMFS); and
disease-free survival (DFS). In calculating the disease-
specific survival, a patient dying of their tumour was a
point event; patients who survived, defaulted follow-up,
or died of other disease were censored. Local recurrence
was established by fibreoptic endoscopy and biopsy or
MRI. Distant metastases were diagnosed on the basis of
clinical symptoms, physical examination, and imaging
methods, including chest radiography, bone scans, MRI
and abdominal sonography.
All statistical analyses were performed using the Statis-
tical Package for the Social Sciences (SPSS) 13.0 software
(SPSS Inc., Chicago, IL). The actuarial rates were calcu-
lated by the Kaplan-Meier method, and differences were
compared using the log-rank test. Multivariate analyses
with the Cox proportional hazards model were used to
calculate the hazard ratio (HR) and test independent sig-
nificance by backward elimination of insignificant ex-
planatory variables. Host factors (age and sex) were
included as the covariates in all tests. The criterion for
significance was set at 0.05, and P values were based on
2-sided test results.
Results
Incidence and Survival of CN Palsy
Of the 1892 patients with NPC, 178 (9.4%) had clinical
evidence of CN palsy at presentation including 171
patients with unilateral palsy and 7 with bilateral palsy.
The most common CN palsies among these patients
involved VI, V2 and V3 (49.4%, 44.9% and 35.4%, re-
spectively). In 178 T4 patients, the 5-year survival rates
were as follows: overall survival (OS), 61.0%; disease-
specific survival (DSS), 69.6%; local relapse-free survival
(LRFS), 75.2%; distant metastasis-free survival (DMFS),
73.4%; and disease-free survival (DFS), 55.3%.Differences in the prognostic implications of single and
multiple CN palsy
Of the 178 patients, 74 patients (41.6%) had single CN
palsy and 104 patients (58.4%) had multiple CN palsy.
Significant differences were observed in the 5-year OS
rates (69.8% vs. 54.3%; P = 0.033) between the two
groups with single and multiple CN palsy, but no signifi-
cant differences were observed for DSS (76.1% vs. 64.5%;
P = 0.085), LRFS (73.2% vs. 76.8%; P = 0.783), DMFS
(76.9% vs. 70.5%; P = 0.384) or DFS (59.0% vs. 52.7%;
P = 0.317) rates between the two groups (Figure 1).
The following parameters, which could potentially in-
fluence patient prognosis, were included in the Cox pro-
portional hazards model for multivariate analysis: age
(>median age vs. ≤median age), sex, N classification,
radiotherapy dose (>70 Gy vs. ≤70 Gy), chemotherapy,
and CN palsy (with single and multiple involvement).
The results indicated that the number of CN palsies was
an independent prognostic factor for OS (HR= 1.765;
P = 0.029), but not for DSS, LRFS, DMFS or DFS.
Prognosis of upper and lower CN palsy
Of the 178 patients, 140 patients (78.7%) had upper CN
palsy and 17 patients (9.6%) had lower CN palsy. No sig-
nificant differences were observed for OS (61.2% vs.
67.7%; P = 0.581), DSS (70.1% vs. 72.2%; P = 0.792), LRFS
(75.4% vs. 73.9%; P = 0.729), DMFS (70.1% vs. 86.5%;
P = 0.257) or DFS (52.7% vs. 73.9%; P = 0.212) rates be-
tween the two groups (Figure 2).
The following parameters, which could potentially in-
fluence patient prognosis, were included in the Cox pro-
portional hazards model for multivariate analysis: age
(>median age vs. ≤median age), sex, N classification,
radiotherapy dose (>70 Gy vs. ≤70 Gy), chemotherapy,
and CN palsy (with upper and lower involvement). The
results indicated that the location of CN palsy was not
an independent prognostic factor for OS, DSS, LRFS,
DMFS or DFS.
Prognostic value of different pretreatment durations
Because the patients with CN palsy had different dur-
ation times before clinical diagnosis, it is essential to de-
termine the prognostic value of the pretreatment
duration. The patients with CN palsy in this series were
classified into two groups: Group 1 included patients
with CN palsy with a pretreatment duration within
2 months, and Group 2 had a pretreatment duration
longer than 2 months. A significant difference was
observed for OS (68.7% vs. 43.3%; P = 0.007) between
Groups 1 and 2, but no significant differences were
observed for DSS (74.0% vs. 56.8%; P = 0.222), LRFS
(78.9% vs. 66.8%; P = 0.068), DMFS (72.4% vs. 74.7%;
P = 0.532) or DFS (57.5% vs. 49.7%; P = 0.369) rates be-
tween the two groups (Figure 3).
Figure 1 The overall survival and disease-specific survival curves for the different numbers of CN palsy groups: Group 1, patients with
single CN palsy; Group 2, patients with multiple CN palsy (A and B).
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various prognostic factors in Group 1 and 2 patients
with different pretreatment durations of CN palsy. The
following parameters were included in the Cox propor-
tional hazards model by backward elimination of insig-
nificant explanatory variables: age (>median age vs.
≤median age), sex, N classification, radiotherapy dose
(>70 Gy vs. ≤70 Gy), chemotherapy, and pretreatment
duration (Groups 1 and 2). The results indicated that
pretreatment duration was an independent prognostic
factor for OS (HR= 1.926; P = 0.009) but not for DSS,
LRFS, DMFS or DFS.Further prognostic analysis of patients with different
recovery durations
Because most patients recover from CN palsy within six
months, all patients with CN palsy in this series were
classified into two groups: Group 1 included patients
with a recovery duration within 6 months, and Group 2
included patients with a recovery duration beyond
6 months. Significant differences were observed for
5-year OS (69.1% vs. 41.7%; P < 0.001), DSS (75.8% vs.
54.4%; P = 0.016), LRFS (82.3% vs. 59.5%; P = 0.002) and
DFS (63.9% vs. 36.4%; P = 0.001) rates between Groups 1
and 2, but no significant difference was observed for
Figure 2 The overall survival and disease-specific survival curves for the different section groups: Group 1, patients with upper CN
palsy; Group 2, patients with lower CN palsy (A and B).
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1 and 2 (Figure 4).
A multivariate analysis was performed to adjust for
various prognostic factors in Group 1 and 2 patients
with different recovery durations of CN palsy. The fol-
lowing parameters were included in the Cox propor-
tional hazards model by backward elimination of
insignificant explanatory variables: age (>median age vs.
≤median age), sex, N classification, radiotherapy dose
(>70 Gy vs. ≤70 Gy), chemotherapy, and recovery dur-
ation (Groups 1 and 2). The results indicated that recov-
ery duration was an independent prognostic factor for
OS (HR= 2.485; P < 0.001), DSS (HR= 2.065; P = 0.016),LRFS (HR= 3.051; P = 0.001) and DFS (HR= 2.440;
P < 0.001) but not for DMFS.
Discussion
In this study, the incidence of cranial nerve palsy (9.4%)
was similar to that found in previous research (approxi-
mately 8.0 to 12.4%) [1]. The AJCC has recommended
that CN involvement be assessed through neurological
evaluation rather than cross-sectional imaging [2]. Be-
cause CN involvement is considered a poor prognostic
indicator in NPC patients, those with CN involvement
are staged as T4. CN palsy frequently accompanied
skull-base invasion in upper CN palsy and carotid sheath
Figure 3 The overall survival and disease-specific survival curves for the different pretreatment duration groups: Group 1, patients
with CN palsy with a pretreatment duration within 2 months; Group 2, patients with a pretreatment duration beyond 2 months
(A and B).
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frequently approaches from basicranial to intracranial or
orbital sites and involves upper CNs. In addition, the CN
V and VI are located in the sites most prone to tumor
invasion and extend a long distance; their involvement
can often be observed.
The results of this study showed that NPC patients
with multiple CN palsy have poorer OS than those with
single CN palsy, but the difference in disease-specific
survival rates was not significant. Patient prognosis islikely related to the extent and volume of the tumor, and
the incorporation of the primary tumor volume may lead
to a further refinement of treatment outcome [3,11].
NPC patients with multiple CN palsy may require more
cycles of induction or adjuvant chemotherapy in
addition to the base of concomitant chemotherapy and
radiation [12,13]. However, the results of our study
revealed that the DSS was not significant for different
groups with single and multiple CN palsy, which may
account for the observation that different numbers of
Figure 4 The overall survival, disease-specific survival, local relapse-free survival and disease-free survival curves for the different
recovery duration groups: Group 1, recovery duration of patients with CN palsy within 6 months; Group 2, recovery duration beyond
6 months (A/B/C/D).
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CN palsy with upper or lower involvement was not
found to be a significant factor influencing OS, DSS,
LRFS or DFS. This result was likely related to anatomy.
CN palsy often accompanies basicranial, intracranial or
orbital invasion in upper CN palsy and carotid sheath
erosion in lower CN palsy. Upper CN involvement was
associated with recurrence from the primary invasion; in
contrast, lower CN involvement accompanied lymph
node erosion, which could increase metastasis, exhibit-
ing the hazard criteria consistent with the staging classi-
fication system [14]. Advanced T and N stages had
similar prognoses.
In 2010, the NCCN recommended that the treatment
regimen for NPC patients with CN involvement should
consist of concurrent chemoradiotherapy plus adjuvant
or induction chemotherapy as the standard treatment.Despite the fact that the pretreatment duration was
associated with significantly poorer OS in this study, the
difference in DSS was not significant between the groups
with different pretreatment durations. Moreover, no
other study has assessed the relationship between pre-
treatment duration and prognosis. Further studies are
required to determine whether more regimens and
cycles of chemotherapy would add a benefit to radio-
therapy for patients with different pretreatment dura-
tions. These findings may have implications for further
improvements in treating advanced-stage tumors with
different pretreatment durations.
In our study, recovery duration was an independent
prognostic factor for 5-year LRFS in patients with NPC.
In a previous study, CN recovery correlated significantly
with the pretreatment duration of CN palsy, the time
course of clinical tumor regression, and neurologic
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recommended a need for continuous and close neuro-
logic surveillance. In addition, patients with NPC had a
higher rate of radiation-induced CN palsy, with a me-
dian latent period of 7.6 years (range, 0.3-34 years) [16].
It is essential to examine CN involvement before treat-
ment and to estimate the cause from clinical data; in
particular, MRI has been shown to be a valuable tool for
detecting and defining the extent of CN involvement in
NPC [17]. The results of our study showed that patients
whose recoveries from CN palsy required longer than
six months had poorer OS, DSS, LRFS and DFS. We
hypothesize that recovery duration is related to recur-
rence, which leads to poor survival. Thus, patients with
longer recovery durations require follow-up after six
months to detect recurrence and sequelae that influence
patient prognosis.
Conclusions
In conclusion, recovery duration is an independent prog-
nostic factor for NPC with CN palsy and is related to re-
currence that leads to poor survival. Moreover, recovery
duration requires close surveillance and different treat-
ment regimens.
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